Brivaracetam, commercially available as Briviact®, is an established antiepileptic medication approved for focal epilepsy management. It is used in conjunction with other medications to help control seizures. This drug is designed to offer pharmacologic differentiation from levetiracetam, including higher SV2A affinity and improved tolerability in select patients. Major patents for Briviact® are set to expire around mid of 2026. Which means that the brivaracetam generic versions could soon become available in the market. This presents an important opportunity for manufacturers to develop and commercialize brivaracetam generic products that expand patient access.

As Briviact® approaches patent expiration, understanding the associated brivaracetam generic development pathway becomes increasingly important. But, to contextualize this opportunity, it is essential first to understand brivaracetam’s clinical development. Also, its regulatory positioning and therapeutic role in epilepsy management. This article reviews the patent landscape, market dynamics, and bioequivalence study design considerations shaping the brivaracetam generic opportunity.

An introduction to brivaracetam

Brivaracetam is an antiepileptic adjunct for partial epilepsy. Approved in 2016 for patients ≥16 years, the indication now includes patients from 1 month (FDA) and 2 years (EMA).

As a derivative of racetam, Brivaracetam regulates neuron activity by binding to the SV2A protein. Clinical trials show that the daily dose of 50-200 mg significantly reduces the frequency of seizures compared to placebo. Drugs are generally well tolerated, but side effects may include sleepiness, tremor, fatigue, and mental symptoms. It is available in the form of tablets, oral solutions, and intravenous solutions.

Scientific and clinical overview

Brivaracetam was designed to optimize SV2A interaction, offering 15–30 times greater affinity and faster brain penetration than levetiracetam. A study pooled data from three clinical trials and evaluated brivaracetam as an additional therapy for drug-resistant epilepsy. The study focused on second-tonic clonic seizures. 

The main findings of the study included: 

• Patients receiving 50-200 mg daily showed a significant reduction in seizures compared to placebo. 
• Nearly one-third of patients achieved seizure freedom during the 12-week observation period.

These results are due to the unique molecular targeting of the drug and its pharmacodynamic properties.

Mechanism of action and pharmacology

While both brivaracetam and levetiracetam target SV2A, brivaracetam is pharmacologically distinct. A critical differentiator identified in radioligand studies is that brivaracetam labels twice as many binding sites as levetiracetam in the human cortex. This expanded occupancy, combined with its 15 to 30 fold higher affinity, likely accounts for its distinct clinical profile and ability to suppress seizures at lower doses.

The clinical significance of SV2A modulation by Brivaracetam involves stabilizing the protein’s conformation to reduce excitatory neurotransmission. Preclinical evidence confirms that Brivaracetam achieves this suppression without the cognitive or motor impairment often seen with other ASMs. These molecular properties, particularly the high lipophilicity, fundamentally dictate the drug’s rapid movement through the body.

Brivaracetam’s unique molecular design and interaction with synaptic vesicle protein 2A drive these clinical outcomes. This differentiates it from earlier antiseizure medications.

Pharmacokinetics/Pharmacodynamics

Brivaracetam exhibits high oral bioavailability (~100%), rapid absorption (T_max: 1-2 hours), and linear PK across doses. The liver extensively metabolizes brivaracetam, primarily through hydrolysis of the acetamide group (not P450-dependent). And secondarily through hydroxylation mediated by CYP2C19. It has a half-life of ~9 hours, requiring no routine monitoring but dose adjustments in hepatic impairment.

What makes this drug a significant opportunity in the market?

Brivaracetam presents a strong commercial opportunity due to significant market growth and changing health dynamics. The global brivaracetam generic market opportunity, estimated at USD 1.5 billion in 2024, is projected to reach USD 2.5 billion by 2033, reflecting a robust 6.5% CAGR during the forecast period 2026-2033. The shift from a niche specialty market to a broad generic market following key patent expirations drives this growth path. Some basic drivers defining this opportunity are as follows: 

• Increased clinical demand
• Generic market transformation 
• Manufacturing accessibility 
• Potential for therapeutic expansion 
• Formulation innovation 
• Strategic regional dynamics

These factors create a crucial chance for stakeholders to get early regulatory approvals, improve production processes, and strategically place themselves in rapidly growing niche markets before the market becomes fully established. 

While these factors facilitate market entry, patent laws and regulatory protections for brivaracetam determine the timing and feasibility of generic launch, as discussed below.

Intellectual property and regulatory exclusivity of brivaracetam

A layered patent strategy and regulatory protections define the brivaracetam generic landscape and shape the timing of market entry. The following analysis maps the critical expiration dates and their strategic implications for manufacturers and competitors:

Protection category	Identifier/Number	Scope & coverage	Effective expiration date	Strategic impact
Core Patent	US 6,911,461	Drug substance: Brivaracetam compound (composition of matter)	Aug 21, 2026 (Incl. PED)	Primary Barrier: Expiration allows for the legal manufacturing of the active ingredient.
Secondary Patent	US 8,435,564	Pharmaceutical compositions; stability and excipients for solid oral forms	~2026–2028	Manufacturing Hurdle: Limits specific tablet compositions; complicates generic efforts to achieve bioequivalence (TE code “AB”).
Secondary Patent	US 10,729,653	Oral solution and IV injection formulations; controlled release	April 9, 2030	Key Longevity Barrier: Specific to NDAs 205837 and 205838; protects non-tablet markets.
Secondary Patent	US 8,563,036	Tablet formulations with specific excipients for enhanced dissolution	~2030	Secondary Tablet Barrier: Protects specific high-performance oral delivery profiles.
Regulatory Exclusivity	PED (Pediatric)	6-month extension resulting from studies in patients ≥1 month old	Aug 21, 2026	Extends the ‘461 patent (and other listed patents) by 180 days.
Regulatory Exclusivity	NCE (New Chemical Entity)	5-year statutory protection for new active ingredients	Expired (2021)	No longer prevents ANDA filings; allows for active Paragraph IV challenges.

The expiration of the core composition of matter patent in August 2026 represents a pivotal market inflection point. However, secondary formulation patents extending to 2030 will continue to protect the oral solution and intravenous markets. 

Therefore, generic manufacturers need to carefully decide which drug formulations to focus on first. They must weigh the risks of patents against the profit potential, as active Paragraph IV challenges change the competitive market.

Market dynamics and commercial potential

Brivaracetam’s market performance from 2022 to 2027 shows the ongoing challenge between its clinical benefits and the effects of patent expiration. The drug’s strong SV2A binding and good safety record have led to steady revenue growth. However, the patent expiration in August 2026 will be a key moment that changes the competitive landscape. How quickly and deeply revenue declines will depend not only on the U.S. patent expiry but also on varying regulations and protections in different countries that affect market access. 

Projected revenue erosion and assumptions: While current projections show growth until the core expiry, the entry of generics is expected to erode 80-90% of branded revenue within 12 months of launch:

Year	Projected Revenue (USD)	Critical Market Assumption
2024	$760 Million	Continued adoption in pediatric and adult adjunctive therapy.
2025	$650 – 800 Million	Peak branded revenue; market preparation for generic entry.
2026	$650 Million	Inflection Point: Core expiry Aug 21; initial tablet erosion begins Q4.
2027	$120 Million	Market Erosion: 80% revenue loss assumed as generic tablets capture share.

Stakeholders must prepare for a substantial and imminent “patent cliff” expected to occur in late August 2026. This crucial point will likely lead to a wave of generic alternatives entering the market, potentially disrupting current product lines and pricing strategies.

Moving on, the following section discusses the key actions needed to succeed in the brivaracetam generic market. These actions will help early entrants stand out from those who enter later.

Key development actions for generic entry 

1. Successful brivaracetam generic entry requires strategic alignment of development timelines with patent expiration:

• Manufacturers should prioritize immediate-release (IR) tablets to capitalize on the August 2026 core patent expiry. While also recognizing the elevated patent risk associated with oral solution and intravenous formulations protected until 2030. 
• When developing a formulation, it is important to choose excipients that do not infringe on existing patents. These excipients should help achieve bioequivalence while reducing the risk of encountering secondary patent claims.

2. Bioequivalence (BE) studies need careful planning and execution:

• They usually involve giving a single dose to healthy volunteers and comparing results over two different periods. Researchers support these studies by providing detailed dissolution profiling in various media. 
• They also use validated LC–MS/MS methods to accurately measure how quickly the body absorbs the drug. Evaluation under fasting and, where required by regulatory guidance, fed conditions is necessary to meet FDA and EMA expectations.

Planning effective BE studies requires clear study designs that meet regulatory standards. For brivaracetam, the FDA provides specific guidelines, listings in the Orange Book, and past decisions that explain the requirements needed to show bioequivalence for immediate-release seizure medications. 

In line with these expectations, Credevo has developed bioequivalence study protocols for 10 blockbuster drugs (including Brivaracetam) based on these FDA guidelines. It includes insights from the Orange Book and suggested study designs. These protocols can be a helpful guide for sponsors when they are in early development, evaluating feasibility, or discussing regulatory strategies. It can also be adjusted for specific formulations or regions. Click here to learn more: https://credevo.com/s/bioequivalence-study-protocol-catalogue/.

3. Being ready for regulations is crucial in today’s competitive market, where many products already have approvals:

• To enter the market on time, manufacturers should complete their Chemistry, Manufacturing, and Controls (CMC) documentation, have at least six months of stability data ready when they submit, and develop smart Paragraph IV certification strategies.
• Additionally, companies need to be able to scale operations. This includes reliable API sourcing, affordable manufacturing, and diverse distribution methods. These steps will help them benefit from increased sales. This strategy is critical, especially as generic entry is expected to reduce brand revenues by approximately 80–90% within the first year after launch.
• To maintain a strong market position, teams should work together early on in areas like formulation, bioequivalence, regulations, and sales.

Conclusion

Brivaracetam presents a great opportunity for generic manufacturers due to its upcoming patent expiration, unique pharmacological properties, and ongoing demand in the market. To succeed, companies need to have a solid plan for creating their products, conduct bioequivalence studies on time, and be ready for regulatory approval in a competitive environment. Manufacturers that align development timelines with patent expiration, focus on low-risk formulations, and operate efficiently will be better positioned to succeed in the brivaracetam market after exclusivity ends.

---

Are you currently planning or evaluating a bioequivalence study for brivaracetam or similar immediate-release formulations? 

You may contact our team for support with the design of your bioequivalence (BE) studies and to discuss your specific requirements for conducting bioavailability/bioequivalence (BA/BE) studies.

Kindly share your study requirements using the form below, and our team will review the information and connect with you to discuss your needs in detail.

---